

UCSF

UC San Francisco Previously Published Works

Title

Congenital Heart Disease–Causing Gata4 Mutation Displays Functional Deficits In Vivo

Permalink

<https://escholarship.org/uc/item/2hw8b3rx>

Journal

PLOS Genetics, 8(5)

ISSN

1553-7390

Authors

Misra, Chaitali
Sachan, Nita
McNally, Caryn Rothrock
[et al.](#)

Publication Date

2012

DOI

10.1371/journal.pgen.1002690

Peer reviewed

Congenital Heart Disease–Causing *Gata4* Mutation Displays Functional Deficits *In Vivo*

Chaitali Misra¹, Nita Sachan^{2*}, Caryn Rothrock McNally², Sara N. Koenig¹, Haley A. Nichols², Anuradha Guggilam^{1,3}, Pamela A. Lucchesi^{1,3}, William T. Pu⁴, Deepak Srivastava^{5,6,7}, Vidu Garg^{1,3,8*}

1 Center for Cardiovascular and Pulmonary Research and the Heart Center, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, United States of America, **2** Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, **3** Department of Pediatrics, The Ohio State University, Columbus, Ohio, United States of America, **4** Department of Cardiology, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America, **5** Gladstone Institute of Cardiovascular Disease, University of California San Francisco, San Francisco, California, United States of America, **6** Department of Pediatrics, University of California San Francisco, San Francisco, California, United States of America, **7** Department Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America, **8** Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, United States of America

Abstract

Defects of atrial and ventricular septation are the most frequent form of congenital heart disease, accounting for almost 50% of all cases. We previously reported that a heterozygous G296S missense mutation of *GATA4* caused atrial and ventricular septal defects and pulmonary valve stenosis in humans. *GATA4* encodes a cardiac transcription factor, and when deleted in mice it results in cardiac bifida and lethality by embryonic day (E)9.5. *In vitro*, the mutant *GATA4* protein has a reduced DNA binding affinity and transcriptional activity and abolishes a physical interaction with *TBX5*, a transcription factor critical for normal heart formation. To characterize the mutation *in vivo*, we generated mice harboring the same mutation, *Gata4* G295S. Mice homozygous for the *Gata4* G295S mutant allele have normal ventral body patterning and heart looping, but have a thin ventricular myocardium, single ventricular chamber, and lethality by E11.5. While heterozygous *Gata4* G295S mutant mice are viable, a subset of these mice have semilunar valve stenosis and small defects of the atrial septum. Gene expression studies of homozygous mutant mice suggest the G295S protein can sufficiently activate downstream targets of *Gata4* in the endoderm but not in the developing heart. Cardiomyocyte proliferation deficits and decreased cardiac expression of *CCND2*, a member of the cyclin family and a direct target of *Gata4*, were found in embryos both homozygous and heterozygous for the *Gata4* G295S allele. To further define functions of the *Gata4* G295S mutation *in vivo*, compound mutant mice were generated in which specific cell lineages harbored both the *Gata4* G295S mutant and *Gata4* null alleles. Examination of these mice demonstrated that the *Gata4* G295S protein has functional deficits in early myocardial development. In summary, the *Gata4* G295S mutation functions as a hypomorph *in vivo* and leads to defects in cardiomyocyte proliferation during embryogenesis, which may contribute to the development of congenital heart defects in humans.

Citation: Misra C, Sachan N, McNally CR, Koenig SN, Nichols HA, et al. (2012) Congenital Heart Disease–Causing *Gata4* Mutation Displays Functional Deficits *In Vivo*. *PLoS Genet* 8(5): e1002690. doi:10.1371/journal.pgen.1002690

Editor: Scott Baldwin, Vanderbilt University, United States of America

Received: November 16, 2011; **Accepted:** March 20, 2012; **Published:** May 10, 2012

Copyright: © 2012 Misra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the March of Dimes Birth Defects Foundation (5-FY03-157) and the NIH/NHLBI (R01 HL088965). The funders had no role in study design, data collection and analysis, decision to publish or preparation of manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: vidu.garg@nationwidechildrens.org

‡ Current address: Indian School of Business (ISB), Hyderabad, India

Introduction

Congenital heart defects (CHD) are the most prevalent of all human birth defects with an estimated incidence of 6–8 per 1,000 live births [1,2]. Defects of cardiac septation, which encompass atrial and ventricular septal defects, may occur as an isolated defect or in combination with other cardiac malformations. Defects of atrial and ventricular septation are the most common type of CHD and account for 50% of all cases of CHD. If unrepaired, these defects result in ventricular dilation and heart failure, pulmonary overcirculation leading to pulmonary vascular disease, atrial enlargement predisposing to atrial arrhythmias and ultimately a decreased life expectancy. The etiology for atrial and ventricular septal defects is multifactorial with genetic and environmental factors playing important roles [3,4].

Monogenic etiologies for atrial and ventricular septal defects have been primarily discovered by studying large families with

autosomal dominant forms of septal defects using traditional linkage approaches [5,6]. The first genetic etiology for atrial septal defects was the discovery that mutations in the transcription factor, *TBX5*, are a cause of septation defects in the setting of Holt-Oram syndrome, which is characterized by cardiac and upper limb malformations [7]. *Tbx5* haploinsufficiency in mice accurately mimics the phenotype found in patients with Holt-Oram syndrome [8]. Mutations in the cardiac transcription factor, *NKX2-5*, were identified in families who primarily exhibited non-syndromic atrial septal defects and atrioventricular conduction abnormalities [9]. While targeted deletion of *Nkx2-5* in mice causes developmental arrest during heart tube looping, haploinsufficiency of *Nkx2-5* results in only subtle defects of atrial septation [10,11]. Similarly, mutations in the cardiac transcription factor, *GATA4*, have also been linked to atrial and ventricular septal defects [12,13,14,15,16]. *Gata4* is necessary for normal cardiac development as mice with targeted deletion of *Gata4* display embryonic

Author Summary

Cardiac malformations occur due to abnormal heart development and are the most prevalent human birth defect. Defects of atrial and ventricular septation are the most common type of congenital heart defect and are the result of incomplete closure of the atrial and ventricular septa, a process required for formation of a four-chambered heart. The molecular mechanisms that underlie atrial and ventricular septal defects are unknown. We previously published a highly penetrant autosomal dominant mutation (G296S) in *GATA4*, which was associated with atrial and ventricular septal defects in a large kindred. The disease-causing mutation has a spectrum of biochemical deficits affecting both DNA binding and protein-protein interactions. Here, we report the generation and phenotypic characterization of mice harboring the orthologous mutation in *Gata4* (G295S). While homozygous mutant mice display embryonic lethality and cardiac defects, the phenotype is less severe than *Gata4*-null mice. A subset of *Gata4* G295S heterozygote mice display a persistent interatrial communication (patent foramen ovale) and stenosis of the semilunar valves. Molecular characterization of the mutant mice suggests that the *Gata4* G295S mutant protein results in diminished expression of *Gata4* target genes in the heart and functional deficits in cardiomyocyte proliferation. Thus, cardiomyocyte proliferation defects may contribute to defects of cardiac septation found in humans with *GATA4* mutations.

lethality and defects in ventral morphogenesis associated with failure to form a single ventral heart tube [17,18]. Subsequent studies have demonstrated that *Tbx5*, *Nkx2-5*, and *Gata4* interact to regulate distinct developmental processes during heart development [19,20,21]. While many of the human mutations are predicted to result in haploinsufficiency, little is understood about the underlying mechanism by which reduced transcription factor dosage causes defects in cardiac septation.

We reported a large pedigree with autosomal dominant congenital heart disease that was associated with a mutation of a highly conserved glycine residue to a serine at codon 296 (G296S) [12]. The affected family members had a spectrum of cardiac phenotypes, primarily atrial and ventricular septal defects and pulmonary valve stenosis [12]. *In vitro* experiments demonstrated that the mutant *Gata4* protein had a greatly reduced affinity for its binding element with an associated decrease in transcriptional activity and disrupted a novel interaction between *Gata4* and *Tbx5* [12]. Subsequently, two other families have been reported with a *GATA4* G296S mutation, and affected members display a similar phenotype of atrial septal defects and incompletely penetrant pulmonary valve stenosis [22]. While *Gata4* has been shown to be important for several critical processes during heart development [23,24,25,26], the pathogenesis of heart malformations in humans with the G296S missense mutation in *GATA4* is not as well understood.

To identify the functional deficits of the *GATA4* G296S mutation *in vivo*, we generated and characterized transgenic mice that contain the orthologous G295S mutation in the *Gata4* murine locus. Here, we show that homozygous *Gata4* G295S knock-in (ki) mice (*Gata4* G295S^{ki/ki}) display normal ventral morphogenesis but early embryonic lethality after the linear heart tube stage. Histologic analysis demonstrates a thin ventricular myocardium in the *Gata4* G295S^{ki/ki} embryos, which is associated with a cardiomyocyte proliferation defect. Molecular characterization of these mutant embryos demonstrates that expression of *Gata4*

target genes is decreased in the heart. Echocardiographic examination of heterozygote (*Gata4* G295S^{ki/wt}) mice found subtle atrial septal defects and semilunar valve stenosis. Embryonic cardiomyocytes from heterozygote mice display cardiac proliferation deficits. Consistent with functional deficits for the *Gata4* G295S mutation, compound heterozygote mice harboring only a single *Gata4* G295S mutant allele in the early myocardium recapitulated the phenotype seen in *Gata4* G295S^{ki/ki} embryos. These studies demonstrate the generation of a mouse model for human cardiac malformations and suggest that abnormal cardiomyocyte proliferation may contribute to human atrial and ventricular septal defects caused by mutations in *GATA4*.

Results

Generation and phenotypic characterization of heterozygote *Gata4* G295S^{ki/wt} mice

In order to determine the *in vivo* functional deficits of the human CHD-causing *GATA4* G296S mutation, we generated mice harboring the orthologous mutation at codon 295 in the murine *Gata4* gene (G295S). Using a previously published targeting construct, we mutated the nucleotide from G to A resulting in a glycine to serine substitution in exon 3 which contains the C-terminal zinc finger of *Gata4* [27] (Figure 1A). Successfully targeted ES cell clones were identified by Southern analysis and direct sequencing and injected into host blastocysts to generate chimeras. Germline transmission of the targeted G295S knock-in allele (G295S^{ki}) was detected by Southern blotting in chimeric mice and confirmed by direct sequencing in heterozygous and homozygous mice (Figure 1B–1C and data not shown).

Although the *Gata4* G295S^{ki/wt} heterozygote mice appeared grossly normal, we examined these mutant mice for cardiac structural and functional abnormalities using transthoracic echocardiography. In a genotype-blinded fashion, M-Mode, 2-D pulsed and color-flow Doppler studies were performed in 8 and 16 week old *Gata4* G295S^{ki/wt} mice and their wildtype littermates. Intermittent shunting of blood was noted between the left and right atria in 10/12 *Gata4* G295S^{ki/wt} mice as compared to only 1/9 wildtype littermates (p value<0.05) (Figure 2A–2C). The intermittent atrial communication defect is a patent foramen ovale, which was also found in mice heterozygous for *Nkx2-5*, a gene also implicated in human atrial septal defects [11]. Quantitative pulsed Doppler recordings across the pulmonary and aortic valves demonstrated mild aortic stenosis in 4/12 *Gata4* G295S^{ki/wt} mice and pulmonary stenosis in 2/12 *Gata4* G295S^{ki/wt} mouse (Figure 2A and 2D–2M). No evidence of aortic or pulmonary valve stenosis was noted in wildtype littermates (p value<0.05). The left ventricular function, chamber size and wall thickness in *Gata4* G295S^{ki/wt} mice was not statistically different from wildtype littermates (Figure S1). Histologic analysis of *Gata4* G295S^{ki/wt} hearts demonstrated the patent foramen ovale (Figure S2A–S2D) along with thickened aortic (Figure S2E–S2F) and pulmonary valve leaflets (Figure S2G–S2H).

Phenotypic characterization of homozygous *Gata4* G295S^{ki/ki} mice

To determine the *in vivo* functional deficits of the *Gata4* G295S mutation, we interbred *Gata4* G295S^{ki/wt} to generate *Gata4* G295S^{ki/ki} mice. Analysis at postnatal day 7 demonstrated no *Gata4* G295S^{ki/ki} pups indicating that the homozygous knock-in allele is embryonic or early neonatal lethal. To determine the timing of lethality, we performed timed mating and found that *Gata4* G295S^{ki/ki} embryos did not survive beyond embryonic day (E)11.5, and normal Mendelian ratios were noted from E8.5–E10.5




Figure 1. Targeting strategy for generation of *Gata4* G295S knock-in mice. (A) Single nucleotide change resulting in the glycine to serine mutation was introduced into the mouse *Gata4* locus. Partial restriction map of the murine *Gata4* wildtype allele (top), the *Gata4* targeting vector (middle), and successfully targeted allele (bottom) are shown. Homologous recombination results in replacement of wildtype *Gata4* with genomic DNA harboring a substitution of glycine to serine at position 295 into the mouse *Gata4* locus, as well as the incorporation of neomycin cassette surrounded by loxP sites. *Gata4* coding exons are shown as empty boxes, whereas the exon used as a probe used for Southern blot analysis is highlighted by a black bar. NZf, amino-terminal zinc finger (exon 2); CZf, carboxy-terminal zinc finger (exon 3); E4, exon 4; E5, exon 5; E6, exon 6; B, BglI; S, SacI; E, EcoRV; and N, NotI. (B) Germline transmission of mutant allele was confirmed by Southern blotting after digestion of genomic DNA from *Gata4* G295S^{ki/wt} and wildtype mice with BglI. A 3.8 kb wildtype band and a 12.5 kb mutant band using 3' external probe are shown (black bar in A). (C) Direct sequencing confirmed the presence of mutated residue that altered glycine (GGC) to serine (AGC) in DNA from *Gata4* G295S^{ki/ki} embryos. (D) Western blotting demonstrates that levels of Gata4 protein are equivalent in *Gata4* G295S^{ki/ki} hearts (from three different embryos) as compared to wildtype E9.5 hearts. Equal protein loading is shown by Western blotting to GAPDH. doi:10.1371/journal.pgen.1002690.g001

(Table 1). To determine the expression levels of Gata4 mutant protein in *Gata4* G295S^{ki/ki} embryos, we extracted protein from the hearts of E9.5 *Gata4* G295S^{ki/ki} embryos and wildtype littermates. Immunoblotting demonstrated that total Gata4 protein levels in G295S^{ki/ki} embryos were unchanged as compared to wildtype littermates, suggesting that the G295S mutant mRNA was not undergoing decay and resulting in a *Gata4*-deficient mouse (Figure 1D) [28].

Gross examination of *Gata4* G295S^{ki/ki} embryos demonstrated severe growth retardation compared to wildtype and heterozygote littermates at E9.5 and E10.5 (Figure 3 and Figure S3). The mutant embryos did not display defective heart tube fusion or cardiac bifida, as described in mice with targeted deletion of *Gata4* [17,18]. The mutant embryos displayed a linear heart tube and variable amounts of cardiac looping, with some appearing normal while others demonstrate incomplete or delayed looping (Figure 3A–3I and Figure S3).

To further define the morphologic defects in *Gata4* G295S^{ki/ki} embryos, histologic examination of wildtype and mutant embryos was performed. The embryonic hearts of knock-in homozygotes did not reveal any obvious defects in cardiac morphogenesis at

E9.0 and E9.5 (Figure 3J, 3L and 3N and data not shown). However by E10.5, severe thinning of myocardium and associated decreased wall thickness was noted in the ventricles of *Gata4* G295S^{ki/ki} embryos compared with heterozygote littermate controls (Figure 3K, 3M and 3O). The delayed lethality and the presence of a fused heart tube as compared to *Gata4*-null mice suggested that the *Gata4* G295S mutant protein was functioning as a hypomorph *in vivo*.

Expression of Gata4 target genes

In the early embryo, Gata4 is expressed in developing heart along with the visceral and parietal endoderm [29]. Numerous cardiac genes, including α -myosin heavy chain (α -MHC), cardiac troponin-C (cTNC), atrial natriuretic factor (ANF), have been shown to be direct transcriptional targets of Gata4 [29]. *In vitro* transactivation studies suggested that the *Gata4* G295S mutation had decreased ability to activate downstream target genes [12]. To determine if the expression of direct transcriptional targets of Gata4 were altered in the *Gata4* G295S^{ki/ki} mutant hearts, we extracted RNA from E9.5 hearts and analyzed the expression of α -MHC, cTnC, ANF, and myosin light chain 3 (Myl3) by




Figure 2. Atrial septal defects and semilunar valve stenosis in *Gata4* G295S^{ki/wt} mice. (A) Table showing the frequency of cardiac abnormalities identified in *Gata4* G295S^{ki/wt} mice (n=9) and wildtype littermates (n=12). Representative images of color (B, D, E, I, J) and pulsed wave Doppler (C, F, G, K, L) findings are shown. Small atrial communication demonstrated by both (B) color and (C) pulsed wave Doppler in *Gata4* G295S^{ki/wt} mouse. Color Doppler recordings across normal aortic valve of a wildtype mouse (D) and stenotic aortic valve of *Gata4* G295S^{ki/wt} mouse (E). Pulsed Doppler waveforms of flow across the aortic valve in wildtype (F) and *Gata4* G295S^{ki/wt} (G) mice demonstrate increased aortic velocity in mutant mice. (H) Scatter plot showing aortic velocities in wildtype and *Gata4* G295S^{ki/wt} mice. Four *Gata4* G295S^{ki/wt} mice with aortic stenosis are indicated in red. Color Doppler recordings across pulmonary valve of a wildtype (I) and stenotic pulmonary valve in *Gata4* G295S^{ki/wt} mice (J). Pulsed Doppler waveforms across pulmonary valve of wildtype (K) and *Gata4* G295S^{ki/wt} mice (L) show increased velocity in mutant mice. (M) Scatter plot showing velocity across pulmonary valve in wildtype and *Gata4* G295S^{ki/wt} mice. Two *Gata4* G295S^{ki/wt} mice with pulmonary stenosis indicated in red. doi:10.1371/journal.pgen.1002690.g002

quantitative RT-PCR. The expression levels of all four genes were significantly decreased in *Gata4* G295S^{ki/ki} mutant hearts as compared to wildtype controls (Figure 4A). In contrast, the expression of non-Gata4 target genes, *Tbx5* and β -MHC, was unchanged (Figure 4B). Of note, the expression of *Nkx2.5*, and *Mef2c*, cardiac transcription factors which are proposed to be direct Gata4 targets, was also unchanged (Figure 4B) [30,31]. We also did not find any change in expression of *Gata5* and *Gata6* by quantitative RT-PCR (Figure S4). Radioactive *in situ hybridization* was performed to determine if cardiomyocytes in *Gata4* G295S^{ki/ki}

hearts displayed normal markers of differentiation. At E9.5, the expression of *Tbx5*, *Hand1*, and *Hand2* was similar in G295S^{ki/ki} hearts as compared to control littermates (Figure S5).

The cardiac bifida found in *Gata4*-null embryos occurs secondary to loss of Gata4 in the embryonic endoderm [17,18,32,33,34]. *Gata4* G295S^{ki/ki} embryos undergo normal heart tube fusion, suggesting that they overcome this endoderm-mediated defect. We examined the expression of Gata4-responsive endoderm genes, alpha-fetoprotein (*Afp*) and *Sox17*, along with the endoderm transcription factors, *Hex1* and *Hnf4*, that are not direct

Table 1. Distribution of progeny obtained from intercrossing *Gata4* G295S heterozygote mice.

	Wildtype	<i>Gata4</i> G295S ^{ki/wt}	<i>Gata4</i> G295S ^{ki/ki}
P7	21 (33%)	43 (67%)	0 (0%)
E12.5–E14.5	10 (45%)	12 (55%)	0 (0%)
E11.5	9 (20%)	31 (71%)	4 (9%)
E10.5	16 (32%)	24 (47%)	11 (21%)
E9.5	62 (25%)	134 (54%)	52 (21%)
E8.5–E9.0	6 (22%)	15 (56%)	6 (22%)

doi:10.1371/journal.pgen.1002690.t001

transcriptional targets of *Gata4* [35,36]. *Afp* and *Sox17* did not have decreased levels of expression by qRT-PCR in *Gata4* G295S^{ki/ki} embryos when compared to wildtype littermates at three different embryonic timepoints (Figure S6). Actually, the expression levels of *Afp* and *Sox17* were somewhat increased in *G295S^{ki/ki}* embryos

similar to *Hex1* and *Hnf4*, but this maybe secondary to the growth retardation found in mutant embryos (Figure S6).

Gata4 G295S mutation and deficits in cardiomyocyte proliferation

In order to determine the etiology of the thin ventricular myocardium found in E10.5 *Gata4* G295S^{ki/ki} hearts, we measured the levels of cardiomyocyte proliferation and apoptosis in the mutant hearts. In *Gata4* G295S^{ki/ki} embryos, we observed decreased cardiomyocyte proliferation, as assessed by phospho-histone H3 staining at E9.5 in *Gata4* G295S^{ki/ki} embryos as compared to littermate controls (Figure 5A–5C), but no differences in apoptosis as assessed by TUNEL staining were found (data not shown). Consistent with this finding, the mRNA levels of cyclin D2, a direct transcriptional target of *Gata4* that is critical for cell proliferation, was downregulated in homozygous knock-in embryos by qRT-PCR (Figure 5D) [37]. Additionally, the ability of the *Gata4* G295S mutant protein to activate cyclin D2 beta-gal reporter in HeLa cells was significantly reduced as compared to wildtype *Gata4* (Figure 5E).




Figure 3. *Gata4* G295S^{ki/ki} mice display growth retardation and a thin myocardium. Right (A,D,G), left (B,E,H) and frontal (C,F,I) views of embryos are shown. Growth retardation of *Gata4* G295S^{ki/ki} E9.5 embryos (G,H) when compared to wildtype (A,B) and heterozygote littermates (D,E). A fused heart tube with proper looping is found in *Gata4* G295S^{ki/ki} embryos (I) similar to wildtype (C) and *Gata4* G295S^{ki/ki} littermates (F). Coronal sections through *Gata4* G295S^{ki/wt} (J,K) and *Gata4* G295S^{ki/ki} (L,M) embryos at E9.5 (J,L) and E10.5 (K,M). Normal myocardial thickness is found at E9.5 in homozygous mutant embryos (L) while thin myocardium is seen at E10.5 (M) when compared to heterozygote littermate (K). Quantification of ventricular wall thickness in *Gata4* G295S^{ki/wt} and *Gata4* G295S^{ki/ki} embryos at E9.5 (N) and 10.5 (O). RV, right ventricle; LV, left ventricle; red arrow, heart; A, atria; V, ventricle; OFT, outflow tract. Scale bars indicate 200 µm. doi:10.1371/journal.pgen.1002690.g003




Figure 4. Decreased expression of Gata4 target genes in *Gata4 G295S^{ki/ki}* embryonic hearts. (A) Downregulation of ANF, α -MHC, cTnC, and Myl3 in homozygous mutant E9.5 hearts as compared to wildtype littermates as measured by qRT-PCR. *, p value < 0.05. (B) Quantitative RT-PCR demonstrates no significant change in expression levels of Tbx5, Nkx2.5, Mef2C and β -MHC in E9.5 *Gata4 G295S^{ki/ki}* hearts when compared to wildtype littermates.

doi:10.1371/journal.pgen.1002690.g004

Interestingly, we found that mRNA levels of cyclin D2 were also decreased in the hearts of heterozygote *Gata4 G295S^{ki/wt}* embryos (Figure 5D). In order to determine if subtle cardiomyocyte proliferation deficits existed in *Gata4 G295S^{ki/wt}* embryos, we assessed cell proliferation utilizing a fluorescence activated cell sorting (FACS)-based strategy. Hearts were dissected from E11.5 and E13.5 embryos and cardiomyocytes were purified based on cardiac troponin-T expression [38]. *Gata4 G295S^{ki/wt}* embryonic atrial and ventricular cardiomyocytes displayed decreased cell proliferation as compared to cardiomyocytes from wildtype littermates at both E11.5 and E13.5 (Figure 6A–6K). Accordingly, we found that *Gata4 G295S^{ki/wt}* embryos had thinner atrial and compact ventricular layers at E12.5 (Figure 6L–6Q).

In vivo analysis of cell lineage deficits of the Gata4 G295S protein

To assess the functional deficit of the Gata4 G295S mutant protein in different cell lineages *in vivo*, we first generated mice that

were compound heterozygotes for the *Gata4 G295S* mutant allele and a tissue-specific *Cre*, and lineage-specific deletion of the *Gata4* was performed by crossing them with mice with a floxed *Gata4* allele [23]. One fourth of the resultant progeny were predicted to harbor only the mutant allele in specific cardiac cell types. Tissue specific deletion was obtained by expressing *Cre* under the regulation of *Tie2*, which is expressed in endocardium, endothelium along with a subset of hematopoietic cells (presumed to be circulating endothelial progenitor cells); α MHC, which is specific for late embryonic myocardium, with robust *Cre*-mediated excision starting at E9.5; and *Nkx2-5*, which is expressed in early embryonic myocardium starting at E8.0 and also in the pharynx and liver [39,40,41]. Immunohistochemistry for Gata4 demonstrated decreased Gata4 expression in E10.5 embryonic hearts with the *Nkx2-5 Cre* (Figure S7A–S7B) and *Tie2-Cre* (Figure S7C–S7D) in the myocardium and endocardium, respectively. With the α MHC-*Cre*, expression of Gata4 was only mildly decreased in the myocardium likely related to the later onset of




Figure 5. G295S mutation in *Gata4* results in cardiomyocyte proliferation defects. Immunofluorescent staining for phosphohistone H3 (red) along with desmin staining for cardiomyocytes (green) demonstrates decreased cardiomyocyte proliferation in *Gata4* G295S^{ki/ki} (B) as compared to wildtype (A) in histologic sections of E9.5 hearts. V, ventricle. (C) Quantification of phosphohistone H3 (PH3) staining of cardiomyocytes is decreased in *Gata4* G295S^{ki/ki} embryonic hearts when compared to wildtype. *, p value<0.05. (D) Quantitative RT-PCR demonstrates decreased cyclin D2 expression in the E9.5 hearts of both *Gata4* G295S^{ki/wt} and *Gata4* G295S^{ki/ki} embryos. *, p value<0.05. (E) Cyclin D2 β-gal reporter assays using wildtype *Gata4* or *Gata4* G295S mutant plasmids demonstrates that the G295S mutant protein has decreased transactivation ability as compared to wildtype *Gata4*. Error bars represent the standard deviation at least three independent experiments each performed in triplicate. *, p value<0.05. Scale bars indicate 200 μm.
doi:10.1371/journal.pgen.1002690.g005

Cre expression (Figure S7E–S7F). Analysis of these compound heterozygotes allowed for the identification of functional deficits of the *Gata4* G295S protein that were present specific to the early myocardium (em*Gata4*G295S), late myocardium (lm*Gata4*G295S) and endocardium (en*Gata4*G295S). We found that only the em*Gata4*G295S was lethal by post-natal day 10 while the lm*Gata4*G295S and en*Gata4*G295S demonstrated partial lethality (Table S1). Genotyping of E10.5 embryos from the crosses using the *Tie2-Cre* (en*Gata4*G295S) and α MHC-*Cre* (lm*Gata4*G295S) showed the expected genotypes were present in normal Mendelian ratios with no evidence of growth retardation (Figure 7A–7I). This contrasts with the severe growth retardation found in *Gata4*G295S^{ki/ki} embryos (Figure 3 and Figure S3). However, embryos obtained from crosses with *Gata4*^{fllox1/lox} and *Gata4* G295S^{ki/wt};Nkx2-5-*Cre*⁺ (em*Gata4*G295S) demonstrated partial lethality by E10.5 and evidence of severe growth retardation (Figure 7A and 7J–7M). Histologic examination of these three genotypes demonstrated a normal myocardial thickness in en*Gata4*G295S and lm*Gata4*G295S, but myocardial thinning in em*Gata4*G295S embryos (Figure 7E, 7I, and 7M), similar to *Gata4* G295S^{ki/ki} embryos (Figure 3K and 3M). These studies support that the *Gata4* G295S mutant protein has functional deficits in the early myocardium that contributes to a thin myocardium.

Discussion

The *GATA4* G296S mutation has been associated with atrial septal defects and pulmonary valve stenosis in multiple human families [12,22]. *In vitro* studies suggested that GATA4 G296S mutant protein resulted in specific functional deficits including

diminished DNA binding affinity, reduced transcriptional activity and loss of a protein-protein interaction with TBX5. Here, we have generated a knock-in mouse harboring the corresponding G295S mutation in *Gata4*. Phenotypic characterization of these mice demonstrate that the *Gata4* G295S mutation functions as a hypomorph *in vivo* as evidenced by the *Gata4* G295S^{ki/ki} embryos displaying prolonged survival as compared to *Gata4*-null embryos and decreased expression of *Gata4* transcriptional target genes. Consistent with the cardiac phenotype seen in humans with *GATA4* mutations, *Gata4* G295S^{ki/wt} mice also display cardiac abnormalities. In addition, we found that the G295S mutation of *Gata4* results in defects of embryonic cardiomyocyte proliferation both *in vitro* and *in vivo*. These findings suggest a potential role for abnormal cardiomyocyte proliferation in the development of atrial and ventricular septal defects caused by mutations in *GATA4*.

The G295S mutation in *Gata4* may result in multiple functional deficits in the embryonic heart. Mice homozygous for the *Gata4* G295S mutation suffer embryonic lethality before E10.5, which limited our analysis to early myocardial development and precluded analysis of potential functional deficits at later stages of heart development. Conditional deletion of *Gata4* in the endocardium results in defective endocardial-mesenchymal transition (EMT) and hypoplastic endocardial cushions [26]. In addition, we have previously shown the G295S mutation in *Gata4* inhibits an interaction with Tbx5 and *Gata4*-*Tbx5* compound heterozygotes display atrioventricular septal defects [12,21]. It remains unclear if the *GATA4* G296S mutation has a role in formation of the endocardial cushions but one family member with the G296S mutation did have an atrioventricular septal defect [12] and other non-related individuals with *GATA4*




Figure 6. Proliferation deficits in *Gata4* *G295S*^{ki/wt} embryonic cardiomyocytes. (A–I) Cells were isolated from wildtype (WT) and *Gata4* *G295S*^{ki/wt} E11.5 and E13.5 hearts. FACS analyses for cardiac troponin T (cTnT)-positive cells was performed for (A, B) E11.5 atria, (C, D) E11.5 ventricles, (E, F) E13.5 atria, and (G, H) E13.5 ventricles. Proliferating cells are detected by staining with Ki67. Representative data are shown in each panel. (I) FACS analysis of unstained cells used as a control. Quantification of proliferative cardiomyocytes in *Gata4* *G295S*^{ki/wt} mutant hearts as compared to wildtype littermate hearts at E11.5 (J) and E13.5 (K). Experiments were performed in triplicate using pooled hearts and all data are presented as means ± standard deviation; **p* value < 0.05. Coronal sections through the heart of wildtype (L, N) and *Gata4* *G295S*^{ki/wt} (M, O) E12.5 hearts. High magnification images of the atria (L, M) and ventricle (N, O) are shown. Quantitative analysis demonstrates decreased wall thickness in the (P) atria and (Q) compact ventricular myocardium in *Gata4* *G295S*^{ki/wt} as compared to wildtype littermates (*n* = 3 for each genotype). Arrowheads, representative site of measurement; *, *p* value < 0.05. Scale bars indicate 200 μm. doi:10.1371/journal.pgen.1002690.g006

A *Gata4*^{flox/flox} x *Gata4* *G295S*^{ki/wt}; *Tie2-Cre*⁺

<i>Gata4</i> ^{flox/wt}	<i>Gata4</i> ^{flox/wt} ; <i>Tie2-Cre</i> ⁺	<i>Gata4</i> ^{flox/G295S}	<i>Gata4</i> ^{flox/G295S} ; <i>Tie2-Cre</i> ⁺
8 (27.5%)	5 (17.2%)	9 (31%)	7 (24.1%)

***Gata4*^{flox/flox} x *Gata4* *G295S*^{ki/wt}; α MHC-Cre⁺**

<i>Gata4</i> ^{flox/wt}	<i>Gata4</i> ^{flox/wt} ; α MHC-Cre ⁺	<i>Gata4</i> ^{flox/G295S}	<i>Gata4</i> ^{flox/G295S} ; α MHC-Cre ⁺
6 (30%)	5 (25%)	4 (20%)	5 (25%)

***Gata4*^{flox/flox} x *Gata4* *G295S*^{ki/wt}; *Nkx2-5-Cre*⁺**

<i>Gata4</i> ^{flox/wt}	<i>Gata4</i> ^{flox/wt} ; <i>Nkx2-5-Cre</i> ⁺	<i>Gata4</i> ^{flox/G295S}	<i>Gata4</i> ^{flox/G295S} ; <i>Nkx2-5-Cre</i> ⁺
8(33.3%)	5(20.8%)	6(25%)	3(12.5%)




Figure 7. *Gata4* *G295S* mutation has *in vivo* functional deficits in the early embryonic myocardium. (A) Embryonic lethality by E10.5 was found in compound heterozygote mice expressing only a *Gata4* *G295S* mutant allele in early myocardium with the *Nkx2-5-Cre*, but normal Mendelian ratios were seen when the *Gata4* *G295S* mutant allele was expressed in endocardium and late myocardium using *Tie2-Cre* and α -*MHC-Cre*, respectively. Images (B, D, F, H, J, L) and histologic sections (C, E, G, I, K, M) of E10.5 embryos generated with *Tie2-Cre*, which is specific for endocardium (B–E); α -*MHC-Cre*, which is specific for late embryonic myocardium (F–I); and *Nkx2.5-Cre*, which is specific for early embryonic myocardium (J–M), are shown. (L,M) Growth retardation and myocardial thinning were seen in *Gata4* *G295S*^{ki/flox}; *Nkx2-5-Cre*⁺ E10.5 embryos similar to the phenotype of the *Gata4* *G295S*^{ki/ki} embryo. (H,I) The hearts of *Gata4* *G295S*^{ki/flox}; α -*MHC-Cre*⁺ appeared normal at E10.5. (D,E) While the *Gata4* *G295S*^{ki/flox}; *Tie2-Cre*⁺ did not show growth retardation or myocardial thinning, hypocellular endocardial cushions were noted (*). A, atria; V, ventricle; scale bars indicate 200 μ m.
doi:10.1371/journal.pgen.1002690.g007

mutations have atrioventricular septal defects [13]. In our analysis of potential cell lineage deficits for the *Gata4* *G295S* protein, we did find that en*Gata4**G295S* mice, where the endocardium/endothelium expresses only the mutant protein, have somewhat

hypocellular endocardial cushions and display partial lethality by post-natal day 10. This finding suggests that the *Gata4* *G295S* mutation may have functional deficits in the endocardium, potentially by disrupting EMT but additional study is required

(Figure 7). A role for Gata4 and Tbx5 in the endocardium for formation of the atrial septum by regulation of endothelial nitric oxide synthase (*Nos3*) has been proposed, but the early lethality of the *Gata4 G295S^{ki/ki}* embryos did not allow for analysis of this pathway [42]. While this early lethality precluded examination of the development of the cardiac outflow tract and semilunar valves in the *Gata4 G295S^{ki/ki}* embryos, the *Gata4 G295S^{ki/ut}* heterozygotes did develop stenosis of the semilunar valves. This phenotype along with recent publications demonstrating bicuspid aortic valve and aortic valve stenosis in Gata5-null and Gata4;Gata5 compound heterozygote mice suggest that endocardial specific deficits of the G296S protein may contribute to the aortic and pulmonary valve stenosis [43,44].

The phenotypic analysis of *Gata4 G295S^{ki/ki}* mice demonstrates that the Gata4 G295 mutant allele is not a loss of function allele. Initial human genetic studies demonstrated that haploinsufficiency of *GATA4* resulted in cardiac malformations and there was a possibility that the *Gata4 G295* was a null allele [45]. Our data demonstrate that the G295S mutation in *Gata4* results in a selective loss of some Gata4 functions. Specifically, the Gata4 G295S protein is able to activate downstream target genes in the developing endoderm but not in the cardiac mesoderm. Potential mechanisms for this difference may lie in the inability of Gata4 G295S protein to interact with Tbx5 in the mesoderm to activate downstream targets or that Gata4 may function as a transcriptional co-activator in the endoderm and DNA binding is not necessary. The findings from the conditional deletion crosses, as discussed above, also support that the G295S mutant protein has defined functional deficits in different cell lineages. Additional investigation is needed to identify all the potential functions of Gata4 and then determine which are lost with the Gata4 G295S mutation.

Cardiomyocyte proliferation is critical for normal cardiac development, and our findings provide evidence that the *Gata4 G295S* mutation results in myocardial hypoplasia due to diminished cardiac proliferation. This phenotype is at least partially mediated by reduced expression of cyclin D2, a member of the D-cyclin family of cell cycle regulators. Mice lacking any single D-cyclin are viable and do not display obvious cardiac defects [46]. However, compound mutation of all three D-cyclin genes results in embryonic lethality due to cellular proliferation defects, including reduced cardiomyocyte cell division [47]. Our data demonstrate that both homozygote and heterozygote *Gata4 G295S^{ki}* mice display cardiomyocyte proliferation deficits and suggest that this is a possible mechanism for the atrial septal defects seen in these mice.

The generation of the *Gata4 G295S^{ki}* mice provides a mouse model to study human congenital heart defects. This mouse model will be of significant value to study genetic and environment modifiers for cardiac malformations along with allowing for a more mechanistic understanding of the embryologic basis of septation and valvular defects. While the dosage sensitivity of cardiac transcription factors for normal cardiac morphogenesis is generally well accepted, this mouse model demonstrates that specific mutations may have limited functional deficits. The *Gata4 G295S^{ki}* mice which encodes a partially functional mutant protein, offers us a tool to define these abnormalities *in vivo*.

Materials and Methods

Ethics statement

Research was approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern Medical Center (Protocol No. 2008-0094) and Research Institute at Nationwide Children's Hospital (Protocol No. AR09-00040) and

conforms to the Guide for the Care and Use of Laboratory Animals.

Gene-targeted mutagenesis

A strategy similar to Crispino et al., 2001 was used to generate knock-in mice harboring the *Gata4 G295S* mutation. The targeting vector contains an 8.2 kb mouse genomic fragment, which has the 2nd–6th exons of murine *Gata4*. The construct contains a Neomycin resistance cassette flanked by loxP sites, as a positive selection marker, and HSV-tk, as a negative selection marker. Genomic DNA containing the N-terminal of the zinc finger domain of *Gata4* was subcloned into pBluescript II KS (+/–) phagemid (Stratagene). By site-directed mutagenesis, glycine at codon 295 was changed to serine (the codon GGC was changed to AGC). The targeting construct was linearized with PvuI and electroporated into 129SvES cells. Targeted clones were identified by Southern blotting. Six successful targeted ES clones identified by Southern blotting and direct sequencing for the G295S point mutation. Three clones were injected into C57BL/6 blastocysts to generate chimeric mice.

Mouse strains and genotyping

Germline transmission was achieved by mating to C57BL/6 mice. Mice used in this study were on a mixed 129SvEv/C57BL6 genetic background. For genotyping, allelic discrimination assay was used to detect this single nucleotide change in *Gata4* locus by using fluorescent probes. This method combines PCR and mutation detection in a single step. Two TaqMan (Applied Biosystems, CA) probes were used, one for each allele. This method is implemented using the Applied Biosystems 7500Fast and TaqMan reagents to detect this point mutation in *Gata4*. The probe and primer sequences are shown in Table S2.

Breeding and collection of mouse embryos

Mice were maintained on a 0600 to 1800h light–dark cycle, with noon of the day of observation of a vaginal plug defined as E0.5. Mice heterozygous for *Gata4 G295S* mutation were generated and genotyped as described above. Mice heterozygote for *Gata4 G295S* were mated to generate *G295S* homozygote embryos. Pregnant mothers were sacrificed at various embryonic timepoints. Littermates were used as controls for histologic sections, gene expression studies and FACS analysis.

Echocardiographic imaging

Two dimensional and Doppler *in vivo* ultrasound images were obtained in 8 and 16 week old mice using a VisualSonics Vevo2100 imaging system (Ontario, Canada) with a mechanical transducer (MS400). Mice were anesthetized with isoflourane and echocardiograms were performed in a genotype-blinded fashion. Statistical analysis was performed using Fisher's exact test.

Histologic section and radioactive in situ hybridization

For histological analysis, embryos and adult hearts were fixed in 4% paraformaldehyde and paraffin embedded. Hematoxylin and eosin (H and E) staining was carried out on heart sections using standard methodology. *In situ hybridization* was performed as described previously [48] using ³⁵S-labeled antisense probes synthesized with T3, T7, or SP6 RNA polymerase (Maxiscript; Ambion Inc., Austin, TX) from mouse Hand1, Hand2 and Tbx5 cDNA.

Proliferation and apoptosis assays

For the immunostaining studies, histologic sections were defatified in xylene and rehydrated in phosphate buffered

saline (PBS). Proliferation assays were performed using the phosphohistone H3 (PH3) antibody (Upstate Cell Signaling Solutions, Temecula, CA). The sections were permeabilized in 0.3% Triton X-100 in PBS. Sections were then blocked by 3.5% donkey serum in PBS followed by incubation with 1% rabbit anti-phosphohistone H3 antibody overnight at 4°C. Sections were then washed in PBS and Cy3 (1%) secondary antibodies (Vector Laboratories, Burlingame, CA) for 30 min. For cell proliferation studies, contiguous sections were stained for monoclonal mouse anti-human desmin using Cy3-conjugated antibody (Dako, Carpinteria, CA) to label the cardiomyocytes. The percentage of PH3-stained ventricular cardiomyocytes/total number of ventricular cardiomyocytes was calculated by analyzing a minimum of three embryos for each genotype. A minimum of four sections per embryo were analyzed, and the means and standard deviations are shown. Apoptosis (TUNEL) assays were performed using the In Situ Cell Death Detection Kit, Fluorescein (Roche) according to manufacturer instructions. Labeled ventricular cardiomyocytes were counted on a minimum of six sections of control and mutant embryonic hearts. Statistical analysis was performed using Student's *t*-test.

Gene expression analysis

RNA was purified from embryonic hearts (E8.5–E10.5) from mutant embryos and their respective wildtype littermates using Trizol (Invitrogen). Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed using the Taqman Universal PCR Master Mix kit (Applied Biosystems, Foster City, CA). 100 ng of total RNA was used for reverse transcription and amplification in each real-time PCR reaction using Applied Biosystems 7500 real-time PCR machine. Commercially available SYBR Green (Applied Biosystems) PCR mix was utilized for the following genes: ANF, α -MHC, cTnC, Myl3, CyclinD2, Nkx2-5, Tbx5, Mef2C, β -MHC, HNF4, Hex1, alpha-fetoprotein and Sox17. The sequences for primers are in Table S2. Mean relative gene expression was calculated from wildtype and mutant hearts after normalization to 18S ribosomal RNA, minimum of $n = 3$ per group. Statistical analysis was performed using Student's *t*-test, and a *p* value of less than 0.05 was considered significant.

Transactivation assays

HeLa cells were transfected using Fugene 6 (Roche) according to manufacturer's instructions with 200 ng of *Gata4* wildtype and *Gata4 G295S* myc-tagged expression vectors [12], 200 ng of *Cyclin D2* pAUG- β -gal reporter vector [37]. Immunoblots were used to verify appropriate expression. Cells were cultured for 48 h after transfection, harvested and cellular extracts were prepared by sonication and normalized as described previously [49]. Chemiluminescence β -galactosidase (β -Gal) assays were performed using the luminescent β -Gal detection system (Clontech) according to the manufacturer's recommendations, and relative light units were detected using a Tropic TR717 microplate luminometer (PE Applied Biosystems).

Flow cytometry

Embryonic heart samples for fluorescence-activated cell sorting (FACS) were prepared in the following manner: 15–20 embryonic hearts of each genotype were dissected, dissociated to a single cell solution, digested with collagenase type II (Worthington) solution, washed, spun down and resuspended in cardiomyocyte staining buffer. Cells were fixed with BD Cytofix/Cytoperm™ solution, permeabilized and incubated with monoclonal mouse anti-tropoin T (Abcam, Cambridge, MA) and Ki67 (Abcam, Cam-

bridge, MA). Experiments were performed in triplicate and cells were analysed on a LSRII with DiVa software (BD Biosciences, San Jose, CA, USA).

Supporting Information

Figure S1 Summary of M-mode echocardiographic analysis of wildtype and *Gata4 G295^{cut/ki}* mice. (A) Scatter plot showing fractional shortening in wildtype and *Gata4 G295^{cut/ki}* mice at 8 and 16 weeks of age. Scatter plots show (B) left ventricular internal diameter (LVID) at end-diastole, (C) left ventricular internal diameter during systole, (D) left ventricular anterolateral wall (LVAW) thickness at end-diastole, (E) left ventricular anterolateral wall thickness during systole, (F) left ventricular posterior wall (LVPW) thickness at end-diastole, and (G) scatter plot showing left ventricular posterior wall thickness during systole. (JPG)

Figure S2 Patent foramen ovale, aortic valve stenosis and pulmonary valve stenosis in *Gata4 G295^{cut/ki}* murine hearts by histologic section. Interatrial communication in the form of patent foramen ovale (arrowhead in B, D) is found in *Gata4 G295^{cut/ki}* mice (B, D) as compared to wildtype littermate (A, C). (C, D) represent high magnification image of boxed area in (A, B), respectively. Thickening of aortic valve leaflets is found in *Gata4 G295^{cut/ki}* mouse (F) that had aortic valve stenosis by echocardiogram as compared to wildtype (E). Thickened pulmonary valve leaflets in *Gata4 G295^{cut/ki}* mouse are shown (H) as compared to normal leaflets in wildtype littermate (G). RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; AO, aorta; PA, pulmonary artery. Scale bars indicate 200 μ m. (JPG)

Figure S3 Variable cardiac looping of *Gata4 G295^{ki/ki}* embryos during development. (A) Normal cardiac looping in wildtype E10.5 embryo as compared to incomplete looping in *Gata4 G295^{ki/ki}* in E10.5 embryo (B). Red arrow, heart. Scale bars indicate 200 μ m. (JPG)

Figure S4 Expression of *Gata5* and *Gata6* is unchanged in *Gata4 G295^{ki/ki}* embryonic hearts. Quantitative RT-PCR demonstrates no significant change in expression levels of *Gata5* and *Gata6* in E9.5 *Gata4 G295^{ki/ki}* hearts when compared to wildtype littermates. (JPG)

Figure S5 Expression of *Hand1*, *Tbx5* and *Hand2* is unchanged in *Gata4 G295^{ki/ki}* embryos. Coronal sections through E9.5 hearts of *Gata4 G295^{cut/ki}* (A–D) and *Gata4 G295^{ki/ki}* embryos (E–H). Radioactive section in situ hybridization demonstrates mRNA expression of *Hand1* (B,F), *Tbx5* (C,G), and *Hand2* (D,H) in *Gata4 G295^{ki/ki}* embryos is similar to *Gata4 G295^{cut/ki}* littermates. Bright-field images are shown in (A) and (E). A, atria; V, ventricle; OFT, outflow tract. (JPG)

Figure S6 Expression of endoderm genes is not decreased in *Gata4 G295^{ki/ki}* embryos hearts. Expression of the *Gata4* target endoderm genes, (A) alpha-fetoprotein and (B) *Sox17* along with expression of (C) *Hex1* and (D) *HNF4*, genes that are not *Gata4* targets, is shown in E8.5 (red), E9.5 (green) and E10.5 (black) embryos. Solid bars, wildtype embryos; striped bars, *Gata4 G295^{ki/ki}* embryos. (JPG)

Figure S7 Expression of *Gata4* in *Gata4 G295^{ki/flox}*, *Nkx2-5-Cre⁺*, *Gata4 G295^{ki/flox}*, *Tie2-Cre⁺*, *Gata4 G295^{ki/flox}*; α -MHC-Cre⁺

E10.5 embryos. Immunohistochemistry for Gata4 on histologic sections of E10.5 embryos shows decreased myocardial expression (*) and unchanged endocardial expression (arrowhead) in *Gata4* *G295S^{ki/lox}*; *Nkx2-5-Cre⁺* embryo (B) as compared to wildtype littermate (A). Gata4 expression is decreased in the endocardium (arrowhead) of E10.5 *Gata4* *G295S^{ki/lox}*; *Tie2-Cre⁺* embryo (D) compared to wildtype littermate (C). Areas of decreased myocardial expression of Gata4 (arrowhead) in *Gata4* *G295S^{ki/lox}*; α -MHC-*Cre⁺* E10.5 embryos (F) as compared to wildtype littermate (E). Arrowheads, endocardium; V, ventricle; scale bars indicate 200 μ m. (JPG)

Table S1 Distribution of surviving progeny at postnatal day 10 for the following mouse crosses. (JPG)

Table S2 Primer sequences. (JPG)

References

- Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. *J Am Coll Cardiol* 39: 1890–1900.
- Botto LD, Correa A, Erickson JD (2001) Racial and temporal variations in the prevalence of heart defects. *Pediatrics* 107: E32.
- Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, et al. (2007) Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. *Circulation* 115: 3015–3038.
- Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, et al. (2007) Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. *Circulation* 115: 2995–3014.
- Srivastava D (2006) Making or breaking the heart: from lineage determination to morphogenesis. *Cell* 126: 1037–1048.
- Garg V (2006) Insights into the genetic basis of congenital heart disease. *Cell Mol Life Sci* 63: 1141–1148.
- Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, et al. (1997) Mutations in human *TBX5* cause limb and cardiac malformation in Holt-Oram syndrome. *Nat Genet* 15: 30–35.
- Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, et al. (2001) A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor *Tbx5* in cardiogenesis and disease. *Cell* 106: 709–721.
- Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, et al. (1998) Congenital heart disease caused by mutations in the transcription factor *NKX2-5*. *Science* 281: 108–111.
- Lyons I, Parsons LM, Hartley L, Li R, Andrews JE, et al. (1995) Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeobox gene *Nkx2-5*. *Genes Dev* 9: 1654–1666.
- Biben C, Weber R, Kesteven S, Stanley E, McDonald L, et al. (2000) Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene *Nkx2-5*. *Circulation research* 87: 888–895.
- Garg V, Kathiriyi IS, Barnes R, Schluterman MK, King IN, et al. (2003) *GATA4* mutations cause human congenital heart defects and reveal an interaction with *TBX5*. *Nature* 424: 443–447.
- Rajagopal SK, Ma Q, Obler D, Shen J, Manichaikul A, et al. (2007) Spectrum of heart disease associated with murine and human *GATA4* mutation. *J Mol Cell Cardiol* 43: 677–685.
- Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E (2007) *GATA4* sequence variants in patients with congenital heart disease. *J Med Genet* 44: 779–783.
- Zhang W, Li X, Shen A, Jiao W, Guan X, et al. (2008) *GATA4* mutations in 486 Chinese patients with congenital heart disease. *Eur J Med Genet* 51: 527–535.
- Butler TL, Esposito G, Blue GM, Cole AD, Costa MW, et al. (2010) *GATA4* mutations in 357 unrelated patients with congenital heart malformation. *Genet Test Mol Biomarkers* 14: 797–802.
- Molkentin JD, Lin Q, Duncan SA, Olson EN (1997) Requirement of the transcription factor *GATA4* for heart tube formation and ventral morphogenesis. *Genes Dev* 11: 1061–1072.
- Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, et al. (1997) *GATA4* transcription factor is required for ventral morphogenesis and heart tube formation. *Genes Dev* 11: 1048–1060.
- Hiroi Y, Kudoh S, Monzen K, Ikeda Y, Yazaki Y, et al. (2001) *Tbx5* associates with *Nkx2-5* and synergistically promotes cardiomyocyte differentiation. *Nat Genet* 28: 276–280.

Acknowledgments

We thank members of the University of Texas Southwestern Transgenic Mouse Core Facility for assistance with gene targeting, members of the Histology Core at the Research Institute at Nationwide Children’s Hospital and Molecular Pathology Core at University of Texas Southwestern Medical Center for histology and radioactive in situ hybridization, Nanyuan Huang for technical assistance, Dave Dunaway in the Flow Cytometry Core at The Research Institute at Nationwide Children’s Hospital for assistance with cell analysis, B. L. Black for providing us with cyclin D2 reporter plasmid, M. Yanagisawa for the *Tie2-Cre* mice, M.D. Schneider for the α -MHC-*Cre* mice, and E. N. Olson for the *Nkx2-5-Cre* mice.

Author Contributions

Conceived and designed the experiments: CM NS DS VG. Performed the experiments: CM NS CRM SNK HAN AG. Analyzed the data: CM NS CRM AG VG. Contributed reagents/materials/analysis tools: PAL WTP. Wrote the paper: CM VG.

- Moskowitz IP, Kim JB, Moore ML, Wolf CM, Peterson MA, et al. (2007) A molecular pathway including *Id2*, *Tbx5*, and *Nkx2-5* required for cardiac conduction system development. *Cell* 129: 1365–1376.
- Maitra M, Schluterman MK, Nichols HA, Richardson JA, Lo CW, et al. (2009) Interaction of *Gata4* and *Gata6* with *Tbx5* is critical for normal cardiac development. *Dev Biol* 326: 368–377.
- Sarkozy A, Conti E, Neri C, D’Agostino R, Digilio MC, et al. (2005) Spectrum of atrial septal defects associated with mutations of *NKX2.5* and *GATA4* transcription factors. *J Med Genet* 42: e16.
- Pu WT, Ishiwata T, Juraszek AL, Ma Q, Izumo S (2004) *GATA4* is a dosage-sensitive regulator of cardiac morphogenesis. *Dev Biol* 275: 235–244.
- Watt AJ, Battle MA, Li J, Duncan SA (2004) *GATA4* is essential for formation of the proepicardium and regulates cardiogenesis. *Proc Natl Acad Sci U S A* 101: 12573–12578.
- Zeisberg EM, Ma Q, Juraszek AL, Moses K, Schwartz RJ, et al. (2005) Morphogenesis of the right ventricle requires myocardial expression of *Gata4*. *J Clin Invest* 115: 1522–1531.
- Rivera-Feliciano J, Lee KH, Kong SW, Rajagopal S, Ma Q, et al. (2006) Development of heart valves requires *Gata4* expression in endothelial-derived cells. *Development* 133: 3607–3618.
- Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, et al. (2001) Proper coronary vascular development and heart morphogenesis depend on interaction of *GATA-4* with FOG cofactors. *Genes Dev* 15: 839–844.
- Chang YF, Imam JS, Wilkinson MF (2007) The nonsense-mediated decay RNA surveillance pathway. *Annu Rev Biochem* 76: 51–74.
- Molkentin JD (2000) The zinc finger-containing transcription factors *GATA-4*, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. *J Biol Chem* 275: 38949–38952.
- Brown CO, 3rd, Chi X, Garcia-Gras E, Shirai M, Feng XH, Schwartz RJ (2004) The cardiac determination factor, *Nkx2-5*, is activated by mutual co-factors *GATA-4* and *Smad1/4* via a novel upstream enhancer. *J Biol Chem* 279: 10659–10669.
- Dodou E, Verzi MP, Anderson JP, Xu SM, Black BL (2004) *Mef2c* is a direct transcriptional target of *ISL1* and *GATA* factors in the anterior heart field during mouse embryonic development. *Development* 131: 3931–3942.
- Rojas A, Schachterle W, Xu SM, Martin F, Black BL (2010) Direct transcriptional regulation of *Gata4* during early endoderm specification is controlled by *FoxA2* binding to an intronic enhancer. *Dev Biol* 346: 346–355.
- Holtzinger A, Rosenfeld GE, Evans T (2010) *Gata4* directs development of cardiac-inducing endoderm from ES cells. *Dev Biol* 337: 63–73.
- Duncan SA, Nagy A, Chan W (1997) Murine gastrulation requires *HNF-4* regulated gene expression in the visceral endoderm: tetraploid rescue of *Hnf-4(-/-)* embryos. *Development* 124: 279–287.
- Artus J, Piliszek A, Hadjantonakis AK (2011) The primitive endoderm lineage of the mouse blastocyst: sequential transcription factor activation and regulation of differentiation by *Sox17*. *Dev Biol* 350: 393–404.
- Soudais C, Bielinska M, Heikinheimo M, MacArthur CA, Narita N, et al. (1995) Targeted mutagenesis of the transcription factor *GATA-4* gene in mouse embryonic stem cells disrupts visceral endoderm differentiation in vitro. *Development* 121: 3877–3888.
- Rojas A, Kong SW, Agarwal P, Gilliss B, Pu WT, et al. (2008) *GATA4* is a direct transcriptional activator of cyclin D2 and *Cdk4* and is required for cardiomyocyte proliferation in anterior heart field-derived myocardium. *Mol Cell Biol* 28: 5420–5431.
- Walsh S, Ponten A, Fleischmann BK, Jovinge S (2010) Cardiomyocyte cell cycle control and growth estimation in vivo—an analysis based on cardiomyocyte nuclei. *Cardiovasc Res* 86: 365–373.

39. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, et al. (2001) Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. *Dev Biol* 230: 230–242.
40. Gausin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, et al. (2002) Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. *Proc Natl Acad Sci U S A* 99: 2878–2883.
41. McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Srivastava D, et al. (2005) The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. *Development* 132: 189–201.
42. Nadeau M, Georges RO, Laforest B, Yamak A, Lefebvre C, et al. (2010) An endocardial pathway involving *Tbx5*, *Gata4*, and *Nos3* required for atrial septum formation. *Proc Natl Acad Sci U S A* 107: 19356–19361.
43. LaForest B, Andelfinger G, Nemer M (2011) Loss of *Gata5* in mice leads to bicuspid aortic valve. *J Clin Invest* 131: 2876–2887.
44. LaForest B, Nemer M (2011) *GATA5* interacts with *GATA4* and *GATA6* in outflow tract development. *Dev Biol* 358: 368–378.
45. Pehlivan T, Pober BR, Brueckner M, Garrett S, Slaugh R, et al. (1999) *GATA4* haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. *Am J Med Genet* 83: 201–206.
46. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. *Genes Dev* 18: 2699–2711.
47. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagodzón A, et al. (2004) Mouse development and cell proliferation in the absence of D-cyclins. *Cell* 118: 477–491.
48. Garg V, Yamagishi C, Hu T, Kathirya IS, Yamagishi H, et al. (2001) *Tbx1*, a DiGeorge syndrome candidate gene, is regulated by sonic hedgehog during pharyngeal arch development. *Dev Biol* 235: 62–73.
49. Schluterman MK, Krysiak AE, Kathirya IS, Abate N, Chandalia M, et al. (2007) Screening and biochemical analysis of *GATA4* sequence variations identified in patients with congenital heart disease. *Am J Med Genet Part A* 143A: 817–823.